Search

Your search keyword '"Juranic, Z. D."' showing total 4 results
Start Over Author "Juranic, Z. D."
4 results on '"Juranic, Z. D."'

1. One-Step Conversion of Ketones to Conjugated Acids Using Bromoform

Author

Vitnik, V. D., Ivanović, Milovan, Vitnik, Z. J., Dordevic, J. B., Žižak, Željko S., Juranic, Z. D., Juranić, Ivan O., Vitnik, V. D., Ivanović, Milovan, Vitnik, Z. J., Dordevic, J. B., Žižak, Željko S., Juranic, Z. D., and Juranić, Ivan O.

Abstract

Phase-transfer-catalyzed (PTC) reactions of ketones with bromoform and aqueous lithium hydroxide in alcoholic solvent result in the formation of alpha,beta-unsaturated carboxylic acids. The reaction was performed at room temperature for 24h. The corresponding conjugated acids were obtained from cyclic or aromatic ketones, whereas bromo acids were obtained from 4-oxo-piperidine-1-carboxylic acid ethyl ester (13) and 4-oxo-piperidine-1-carboxylic acid tert-butyl ester (14).

Published
2009

3. 2-[(Carboxymethyl)sulfanyl]-4-oxo-4-arylbutanoic Acids Selectively Suppressed Proliferation of Neoplastic Human HeLa Cells. A SAR/QSAR Study

Author

Drakulic, B. J., Juranic, Z. D., Stanojkovic, T. P., and Juranic, I. O.

Abstract

A series of twenty alkyl-, halo-, and methoxy-aryl-substituted 2-[(carboxymethyl)sulfanyl]-4-oxo-4-arylbutanoic acids were synthesized. The new compounds, called CSAB, suppressed proliferation of human cervix carcinoma, HeLa cells, in vitro in a concentration range of 0.644 to 29.48 μM/L. Two compounds exhibit antiproliferative activity in sub-micromolar concentrations (16, 19). Five compounds act in low micromolar concentrations (<2 μM/L). The most active compounds exert lower cytotoxicity toward healthy human peripheral blood mononuclear cells (PBMC and PBMC+PHA) (selectivity indexes > 10). A strong structure−activity relationship, using estimated log P values and BCUT descriptors, was observed.

Published
2005

4. Antimelanoma immunity in vitiligo and melanoma patients.

Author

Juranic ZD, Stanojevic-Bakic N, Zizak Z, Babovic N, Radovic-Kovacevic V, Stanojkovic T, and Dzodic R

Subjects
Adolescent, Adult, Cell Survival, Female, HeLa Cells, Humans, Leukocytes, Mononuclear immunology, Male, Melanoma secondary, Melanoma surgery, Middle Aged, Skin Neoplasms pathology, Skin Neoplasms surgery, Vitiligo pathology, Antigens, Neoplasm immunology, Cytotoxicity, Immunologic immunology, Melanoma immunology, Skin Neoplasms immunology, Vitiligo immunology
Abstract

Cutaneous melanoma and vitiligo are diseases etiology of which evolves around melanocytes. The nature of immunological disturbances associated with these diseases is not elucidated. The experiments performed in this work were aimed to determine antimelanoma immunotoxicity in patients with melanoma and patients with vitiligo. Twelve patients with melanoma, ten patients with vitiligo and seventeen healthy volunteers were studied. The cytotoxicity of PBMC was evaluated indirectly through determination of target melanoma (Fem-x) or control tumor (HeLa) cell survival, in the presence of 15% of AB or autologous sera, by MTT test. The mean values of antimelanoma cytotoxicity in AB serum were similar in both patients groups and in controls. However, the frequency of patients with the enhanced cytotoxicity against melanoma cells, in relation to control tumor cells, was lower in both patients groups than in controls. The intensity of antimelanoma cell-mediated cytotoxicity in melanoma patients, in the presence of autologous serum, was significantly lower in comparison to that found in control subjects and vitiligo patients (p<0.014, in both cases). This indicates that some factors from melanoma patient's sera contribute to impairment of the cytotoxicity of autologous PBMC, while other factors from the serum of vitiligo patients and control subjects enhanced their PBMC antimelanoma cytotoxicity.

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results